Opioid Dependence Pharmacotherapy and Clinical, Criminal Outcomes in Mental...
All 3 opioid-dependence pharmacotherapies — methadone, buprenorphine, and oral naltrexone — were associated with reductions in inpatient substance abuse treatment.
View ArticleOpioid Use Disorder Treatment: Evidence-Based Guideline
A new guideline recommends opioid agonist therapy with buprenorphine-naloxone as first-line for the treatment of opioid use disorder.
View ArticlePain Tolerance in Buprenorphine Maintenance Treatment
Buprenorphine maintenance treatment for opioid dependence may result in hyperalgesia and prevent morphine-associated antinociception.
View ArticleUnit-Dose Packaging of Buprenorphine-Naloxone Effective on Unintentional...
Unit-dose packaging of buprenorphine-naloxone was associated with a reduced number of unintentional exposures of young children presenting to poison centers.
View ArticleTreatment for Opioid Use Disorder Associated With Reduced Risk for...
Few of the individuals who experience an opioid-related overdose had received treatment for opioid use disorder.
View ArticlePoison Control Center Data Detail Peds Exposure to Buprenorphine
Children aged 6 have greater odds of hospital admission than teens with single-substance exposure
View ArticlePhysiologically Based Pharmacokinetic Model to Optimize Buprenorphine...
A physiologically based pharmacokinetic model-based simulation may help optimize buprenorphine therapy during pregnancy.
View ArticleBuprenorphine Diversion Driven by Withdrawal Prevention, Abstinence Maintenance
Researchers deployed a survey to individuals who had received treatment for opioid use disorder to assess their use of buprenorphine.
View ArticleFDA to Review Long-Acting Treatment for Opioid Use Disorder
Pending approval, CAM2038 may be the first long-acting treatment for OUD in both weekly and monthly formulations.
View ArticleHigher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence...
Pregnant women receiving medication therapy for addiction can be prescribed higher doses of buprenorphine without increasing the risk or severity of neonatal abstinence syndrome.
View Article
More Pages to Explore .....